Tobias Bartscht

Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro

Henning Schiller, Tobias Bartscht, Alexander Arlt et al. · International Journal of Clinical Pharmacology and Therapeutics · 2002 · 40 citations

Medicine, Hematology, Oncology +14

A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN)

Dirk Rades, CARLOS A. NARVAEZ, LAURA SPLETTSTÖSSER et al. · Radiotherapy and Oncology · 2019 · 36 citations

Medicine, Oncology, Radiation Oncology +17

Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action

Tobias Bartscht, Benjamin Rosien, Dirk Rades et al. · Molecular Cancer · 2015 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells

Tobias Bartscht, Hendrik Lehnert, Frank Gieseler et al. · Cancer Chemotherapy and Pharmacology · 2012 · 30 citations

Medicine, Cancer Biology, Oncology +16

TGF-β1-induced cell migration in pancreatic carcinoma cells is RAC1 and NOX4-dependent and requires RAC1 and NOX4-dependent activation of p38�MAPK

David P. Witte, Tobias Bartscht, Roland Kaufmann et al. · Oncology Reports · 2017 · 19 citations · Full text

Life Sciences, Cell Biology, Oncology +13